Safety check after stem-cell eye treatment
Part of Eyes & vision clinical trials.
This study follows people who previously received an embryonic stem-cell–derived treatment for macular (central) vision loss. Its goal is to watch for long-term side effects and better understand how safe the treatment is over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously received hESC-RPE cell therapy through an Astellas (AIRM) sponsored eye trial for macular degenerative disease
- You can understand and follow what the study is asking
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
This trial tests a new stem-cell treatment for people with advanced dry age-related macular degeneration (AMD), a condition that causes blurring or loss of central vision. It aims to replace damaged cells in the back of the eye to potentially slow vision loss and improve day-to-day sight.
This early-stage study tests a new cell-based treatment (C.001) for inherited retinal diseases that affect the back of the eye. The treatment may help slow vision loss or improve sight in people with geographic atrophy or Stargardt disease.
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This Phase 1 study tests an experimental transplant made from your own cells to try to improve vision in people with advanced “late dry” age-related macular degeneration (AMD). It focuses first on safety, and may help some participants with limited central vision.
Hear when a new Macular Degenerative Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.